Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SLC25A16 (ImmuneEditome ID:8034)

1. Gene summary of enriched editing regions for SLC25A16

Gene summary

Gene information	Gene symbol	SLC25A16
	Gene ID	8034
	GeneSynonyms	D10S105E\|GDA\|GDC\|HGT.1\|ML7\|hML7
	GeneCytomap	10q21.3
	GeneType	protein-coding
	GeneDescription	solute carrier family 25 member 16\|graves disease carrier protein\|mitochondrial solute carrier protein homolog\|solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16
	GeneModificationdate	20230329
	UniprotID	P16260;V9GYA5;V9GY06;V9GYB8
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr10:68478533-68482168:-	ENST00000439904.3	ENSG00000122912.13	SLC25A16	ncRNA_exonic	FLAM_C,AluSx,AluJo,AluSc,(TA)n,AluSq2,AluSc8,AluSx1,L2b	chr10:68478533-68482168:-.alignment
chr10:68489108-68490088:-	ENST00000265870.6	ENSG00000122912.13	SLC25A16	ncRNA_intronic	AluSc,AluJr,AluSp	chr10:68489108-68490088:-.alignment
chr10:68496906-68497901:-	ENST00000265870.6	ENSG00000122912.13	SLC25A16	ncRNA_intronic	AluSg,AluJb,FLAM_C	chr10:68496906-68497901:-.alignment
chr10:68504106-68505303:-	ENST00000265870.6	ENSG00000122912.13	SLC25A16	ncRNA_intronic	AluY,AluJb,AluSx	chr10:68504106-68505303:-.alignment
chr10:68517572-68525623:-	ENST00000265870.6	ENSG00000122912.13	SLC25A16	ncRNA_exonic	AluSx1,AluSp,AluY,AluSc8,(AAAT)n,L1ME1,L2a,AluYa5,MER44D,AluSq2,AluSg,(AC)n,AluSz,AluSg7,L1MC,AluSx,AluSx3,AluSz6,AluJr4,AluJb,AluSc	chr10:68517572-68525623:-.alignment

Top

2. Tumor-specific enriched editing regions for SLC25A16

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr10:68478533-68482168:-	BRCA	EER	1.1135e-11
ENSG00000122912.13,SLC25A16	BRCA	EAG	2.9897e-16
chr10:68478533-68482168:-	COAD	EER	2.2233e-02
ENSG00000122912.13,SLC25A16	COAD	EAG	1.1602e-02
ENSG00000122912.13,SLC25A16	KICH	EAG	4.9495e-02
ENSG00000122912.13,SLC25A16	KIRP	EAG	1.2138e-02
chr10:68478533-68482168:-	LIHC	EER	4.6362e-02
chr10:68478533-68482168:-	LUAD	EER	3.2055e-02
ENSG00000122912.13,SLC25A16	LUAD	EAG	2.8976e-04
chr10:68478533-68482168:-	LUSC	EER	8.0237e-03
ENSG00000122912.13,SLC25A16	LUSC	EAG	1.1242e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000122912.13,SLC25A16	TGCT	Path	EAG	2.5480e-02	1.3544e-02	0.2785
chr10:68478533-68482168:-	TGCT	Path	EER	2.8578e-02	2.0500e-02	0.2654

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr10:68478533-68482168:-	PRAD	EER	2.1684e-02	1.3412e-02	1.5292e-44

Top

3. Enriched editing regions and immune related genes for SLC25A16

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr10:68478533-68482168:-

KICH

EER

ENSG00000145050,MANF

0.5475

4.3256e-02

1.0028e-07

0.6460

FUS;HNRNPC;TAF15;UPF1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS

chr10:68478533-68482168:-

KIRP

EER

ENSG00000143001,TMEM61

0.1660

4.4089e-02

4.2086e-12

0.4139

TAF15

B_cells_naive

GSVA_HALLMARK_TGF_BETA_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for SLC25A16

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for SLC25A16

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr10:68478533-68482168:-	ACC	EER	Plasma_cells	6.5800e-03	0.3722
ENSG00000122912.13,SLC25A16	ACC	EAG	Plasma_cells	9.0487e-03	0.3586
chr10:68478533-68482168:-	BLCA	EER	NK_cells_resting	7.5002e-04	0.2778
ENSG00000122912.13,SLC25A16	BLCA	EAG	NK_cells_resting	1.1043e-03	0.2496
chr10:68478533-68482168:-	BRCA	EER	T_cells_regulatory_(Tregs)	6.1192e-04	0.1129
ENSG00000122912.13,SLC25A16	BRCA	EAG	Macrophages_M1	1.1180e-04	0.1260
chr10:68478533-68482168:-	CESC	EER	T_cells_CD4_memory_resting	3.9868e-02	-0.1715
ENSG00000122912.13,SLC25A16	CESC	EAG	T_cells_CD4_memory_resting	2.8052e-02	-0.1771
chr10:68478533-68482168:-	CHOL	EER	Mast_cells_activated	6.5050e-03	0.5197
chr10:68478533-68482168:-	COAD	EER	Neutrophils	2.0571e-03	0.2531
chr10:68517572-68525623:-	COAD	EER	Mast_cells_activated	3.1874e-03	0.5560
ENSG00000122912.13,SLC25A16	COAD	EAG	Mast_cells_activated	4.9258e-03	0.2226
chr10:68478533-68482168:-	ESCA	EER	T_cells_gamma_delta	8.2893e-03	0.2185
chr10:68517572-68525623:-	ESCA	EER	T_cells_gamma_delta	4.0443e-02	0.1747
ENSG00000122912.13,SLC25A16	ESCA	EAG	B_cells_naive	2.2121e-03	-0.2410
chr10:68478533-68482168:-	GBM	EER	Neutrophils	8.1513e-03	0.2606
ENSG00000122912.13,SLC25A16	GBM	EAG	Dendritic_cells_resting	1.0828e-02	-0.2489
chr10:68478533-68482168:-	HNSC	EER	T_cells_CD8	2.9731e-03	-0.2259
ENSG00000122912.13,SLC25A16	HNSC	EAG	T_cells_CD8	5.1248e-03	-0.2089
chr10:68478533-68482168:-	KICH	EER	Plasma_cells	5.2838e-04	0.4522
ENSG00000122912.13,SLC25A16	KICH	EAG	Plasma_cells	1.4130e-03	0.4164
chr10:68478533-68482168:-	KIRC	EER	NK_cells_resting	2.7872e-03	-0.1561
ENSG00000122912.13,SLC25A16	KIRC	EAG	NK_cells_resting	1.0597e-03	-0.1705
chr10:68478533-68482168:-	KIRP	EER	Monocytes	9.9221e-03	0.1603
chr10:68517572-68525623:-	KIRP	EER	T_cells_regulatory_(Tregs)	1.6599e-02	-0.2548
ENSG00000122912.13,SLC25A16	KIRP	EAG	Monocytes	7.6251e-03	0.1651
chr10:68517572-68525623:-	LAML	EER	Dendritic_cells_resting	2.1007e-08	0.5741
ENSG00000122912.13,SLC25A16	LAML	EAG	Dendritic_cells_resting	5.2658e-09	0.5817
chr10:68478533-68482168:-	LGG	EER	T_cells_CD4_naive	2.8501e-02	-0.1019
ENSG00000122912.13,SLC25A16	LGG	EAG	T_cells_CD4_memory_activated	4.7440e-02	0.0921
chr10:68478533-68482168:-	LIHC	EER	Macrophages_M1	8.1765e-03	0.1550
chr10:68517572-68525623:-	LIHC	EER	T_cells_gamma_delta	7.2237e-03	0.3162
chr10:68478533-68482168:-	LUAD	EER	T_cells_CD4_memory_resting	4.0770e-05	-0.2039
chr10:68517572-68525623:-	LUAD	EER	T_cells_CD8	1.7961e-02	0.1803
ENSG00000122912.13,SLC25A16	LUAD	EAG	T_cells_CD4_memory_activated	3.7735e-04	0.1733
chr10:68517572-68525623:-	LUSC	EER	Mast_cells_resting	2.8973e-02	0.2266
ENSG00000122912.13,SLC25A16	LUSC	EAG	Macrophages_M0	2.4319e-02	0.1351
chr10:68478533-68482168:-	MESO	EER	NK_cells_activated	1.6088e-02	0.3931
ENSG00000122912.13,SLC25A16	MESO	EAG	NK_cells_activated	5.7532e-03	0.4190
chr10:68478533-68482168:-	OV	EER	Mast_cells_activated	3.6690e-02	0.1413
chr10:68517572-68525623:-	OV	EER	Dendritic_cells_activated	3.6410e-02	0.1937
chr10:68478533-68482168:-	PAAD	EER	T_cells_regulatory_(Tregs)	3.4538e-03	0.2971
ENSG00000122912.13,SLC25A16	PAAD	EAG	T_cells_regulatory_(Tregs)	1.5703e-03	0.3062
chr10:68478533-68482168:-	PCPG	EER	T_cells_CD4_memory_resting	3.4922e-02	-0.1845
ENSG00000122912.13,SLC25A16	PCPG	EAG	T_cells_CD4_memory_activated	3.4086e-02	0.1846
chr10:68478533-68482168:-	PRAD	EER	T_cells_CD4_memory_activated	1.0680e-03	0.1464
ENSG00000122912.13,SLC25A16	PRAD	EAG	T_cells_CD4_memory_activated	5.7094e-04	0.1540
chr10:68478533-68482168:-	SARC	EER	T_cells_CD4_memory_activated	4.2513e-02	0.1840
ENSG00000122912.13,SLC25A16	SARC	EAG	T_cells_CD4_memory_activated	4.7006e-02	0.1802
chr10:68478533-68482168:-	SKCM	EER	T_cells_gamma_delta	3.0266e-02	-0.1373
chr10:68517572-68525623:-	SKCM	EER	Macrophages_M2	1.0049e-02	-0.3036
ENSG00000122912.13,SLC25A16	SKCM	EAG	T_cells_CD4_memory_resting	3.7070e-03	-0.1761
chr10:68478533-68482168:-	STAD	EER	T_cells_CD4_memory_activated	1.2215e-03	0.1887
chr10:68504106-68505303:-	STAD	EER	Monocytes	2.5519e-02	-0.3328
chr10:68517572-68525623:-	STAD	EER	T_cells_follicular_helper	8.2679e-03	0.1776
ENSG00000122912.13,SLC25A16	STAD	EAG	T_cells_gamma_delta	1.5356e-04	0.2144
chr10:68478533-68482168:-	TGCT	EER	B_cells_naive	9.7241e-03	-0.2210
chr10:68517572-68525623:-	TGCT	EER	Dendritic_cells_activated	3.5631e-02	-0.2218
ENSG00000122912.13,SLC25A16	TGCT	EAG	T_cells_CD4_memory_resting	3.4034e-02	-0.1806
chr10:68478533-68482168:-	THCA	EER	Plasma_cells	5.4885e-03	0.1268
ENSG00000122912.13,SLC25A16	THCA	EAG	Plasma_cells	5.4885e-03	0.1268
chr10:68478533-68482168:-	UCEC	EER	Macrophages_M1	3.0489e-02	0.2921
ENSG00000122912.13,SLC25A16	UCEC	EAG	Macrophages_M1	3.1620e-02	0.2802
chr10:68478533-68482168:-	UVM	EER	T_cells_CD4_naive	1.5559e-02	0.3438
ENSG00000122912.13,SLC25A16	UVM	EAG	T_cells_CD4_naive	1.6110e-02	0.3422

Top

6. Enriched editing regions and immune gene sets for SLC25A16

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr10:68478533-68482168:-	BRCA	EER	9.3053e-11	0.2118	3.0822e-06	0.1534	1.3216e-05	0.1433	3.6252e-04	0.1175
ENSG00000122912.13,SLC25A16	BRCA	EAG	6.5776e-11	0.2114	6.7147e-07	0.1617	3.5873e-05	0.1347	1.7049e-02	0.0780
chr10:68478533-68482168:-	LUAD	EER	1.3108e-06	0.2394	3.0041e-03	0.1482	1.6298e-05	0.2140	5.1848e-05	0.2012
ENSG00000122912.13,SLC25A16	STAD	EAG	7.9636e-06	0.2518	1.2064e-02	0.1431	9.6935e-04	0.1874	8.8703e-04	0.1888
chr10:68478533-68482168:-	TGCT	EER	4.4050e-04	0.2973	2.8005e-03	0.2544	1.9809e-04	0.3139	5.8260e-07	0.4130
ENSG00000122912.13,SLC25A16	TGCT	EAG	5.8596e-04	0.2890	2.8205e-04	0.3045	4.9144e-04	0.2928	1.7233e-05	0.3570

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr10:68478533-68482168:-	ACC	GSVA_HALLMARK_PEROXISOME	EER	3.6989e-02	0.2901
chr10:68517572-68525623:-	BLCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.8541e-02	0.3707
chr10:68478533-68482168:-	BRCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	7.3514e-12	0.2237
chr10:68517572-68525623:-	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	9.0102e-05	0.2310
ENSG00000122912.13,SLC25A16	BRCA	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	8.7105e-10	0.1988
chr10:68478533-68482168:-	CESC	GSVA_HALLMARK_PEROXISOME	EER	2.2526e-03	-0.2526
chr10:68517572-68525623:-	CESC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.3173e-02	0.4796
ENSG00000122912.13,SLC25A16	CESC	GSVA_HALLMARK_PEROXISOME	EAG	6.2666e-03	-0.2194
chr10:68478533-68482168:-	CHOL	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	4.9412e-02	-0.3892
ENSG00000122912.13,SLC25A16	CHOL	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	9.4615e-03	-0.4816
chr10:68478533-68482168:-	COAD	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EER	3.3467e-02	0.1761
chr10:68517572-68525623:-	COAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	4.2485e-04	0.6404
ENSG00000122912.13,SLC25A16	COAD	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EAG	1.0608e-02	0.2028
ENSG00000122912.13,SLC25A16	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	1.6701e-02	0.1896
chr10:68517572-68525623:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	1.0735e-03	0.2755
ENSG00000122912.13,SLC25A16	GBM	GSVA_HALLMARK_HYPOXIA	EAG	1.0014e-02	0.2515
chr10:68478533-68482168:-	GBM	GSVA_HALLMARK_HEME_METABOLISM	EER	2.0311e-02	0.2295
chr10:68478533-68482168:-	HNSC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	7.7386e-04	0.2547
ENSG00000122912.13,SLC25A16	HNSC	GSVA_HALLMARK_MYOGENESIS	EAG	5.2780e-03	0.2083
chr10:68478533-68482168:-	KICH	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.5138e-02	0.3260
ENSG00000122912.13,SLC25A16	KICH	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.3299e-02	0.3290
ENSG00000122912.13,SLC25A16	KIRC	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	4.3044e-03	0.1489
chr10:68517572-68525623:-	KIRC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	6.2354e-04	0.3483
chr10:68478533-68482168:-	KIRC	GSVA_HALLMARK_MYC_TARGETS_V1	EER	6.5133e-06	0.2335
ENSG00000122912.13,SLC25A16	KIRP	GSVA_HALLMARK_P53_PATHWAY	EAG	5.2721e-03	-0.1726
chr10:68478533-68482168:-	KIRP	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	3.7728e-02	0.1294
chr10:68517572-68525623:-	LAML	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.5334e-02	0.2686
ENSG00000122912.13,SLC25A16	LAML	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.3917e-02	0.2448
chr10:68478533-68482168:-	LGG	GSVA_HALLMARK_HEME_METABOLISM	EER	1.0258e-04	0.1797
ENSG00000122912.13,SLC25A16	LGG	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	2.3073e-03	0.1412
chr10:68517572-68525623:-	LIHC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2799e-02	-0.2941
chr10:68478533-68482168:-	LIHC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	7.7486e-04	0.1963
ENSG00000122912.13,SLC25A16	LIHC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.2770e-04	0.2201
ENSG00000122912.13,SLC25A16	LUAD	GSVA_HALLMARK_E2F_TARGETS	EAG	2.9609e-04	0.1764
chr10:68478533-68482168:-	LUAD	GSVA_HALLMARK_GLYCOLYSIS	EER	1.1881e-08	0.2806
chr10:68517572-68525623:-	LUAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	2.4162e-04	0.2764
ENSG00000122912.13,SLC25A16	LUSC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.5074e-02	-0.1344
chr10:68478533-68482168:-	LUSC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.8396e-02	-0.1557
chr10:68517572-68525623:-	LUSC	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EER	9.2759e-03	0.2684
ENSG00000122912.13,SLC25A16	MESO	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.8718e-02	0.3613
ENSG00000122912.13,SLC25A16	OV	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.3169e-02	-0.1320
chr10:68478533-68482168:-	OV	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.6517e-02	0.1618
chr10:68478533-68482168:-	PAAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.0584e-02	0.2373
ENSG00000122912.13,SLC25A16	PAAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	7.6817e-03	-0.2600
ENSG00000122912.13,SLC25A16	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.2041e-03	0.1282
chr10:68478533-68482168:-	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.3363e-03	0.1248
ENSG00000122912.13,SLC25A16	READ	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	2.0939e-02	0.3512
chr10:68478533-68482168:-	READ	GSVA_HALLMARK_G2M_CHECKPOINT	EER	2.0859e-02	0.3514
ENSG00000122912.13,SLC25A16	SARC	GSVA_HALLMARK_GLYCOLYSIS	EAG	3.0429e-03	0.2662
chr10:68478533-68482168:-	SARC	GSVA_HALLMARK_GLYCOLYSIS	EER	1.8696e-03	0.2788
ENSG00000122912.13,SLC25A16	SKCM	GSVA_HALLMARK_P53_PATHWAY	EAG	1.6123e-02	0.1463
chr10:68517572-68525623:-	SKCM	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.2112e-02	-0.2713
chr10:68478533-68482168:-	SKCM	GSVA_HALLMARK_P53_PATHWAY	EER	7.1363e-04	0.2131
ENSG00000122912.13,SLC25A16	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	4.7605e-06	0.2577
chr10:68478533-68482168:-	STAD	GSVA_HALLMARK_P53_PATHWAY	EER	9.5128e-05	0.2268
chr10:68517572-68525623:-	STAD	GSVA_HALLMARK_DNA_REPAIR	EER	1.3072e-03	0.2154
chr10:68517572-68525623:-	TGCT	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.2094e-02	0.2411
ENSG00000122912.13,SLC25A16	TGCT	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	7.5503e-06	0.3708
chr10:68478533-68482168:-	TGCT	GSVA_HALLMARK_GLYCOLYSIS	EER	1.7685e-07	0.4298
chr10:68478533-68482168:-	THCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	3.9050e-03	0.1318
ENSG00000122912.13,SLC25A16	THCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.9050e-03	0.1318
chr10:68478533-68482168:-	THYM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.5174e-02	0.2934
ENSG00000122912.13,SLC25A16	THYM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	3.1075e-02	0.2617
chr10:68478533-68482168:-	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	6.1377e-05	0.5133
ENSG00000122912.13,SLC25A16	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	5.6523e-05	0.4994

Top

7. Enriched editing regions and drugs for SLC25A16

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr10:68478533-68482168:-	ACC	AZD.0530	EER	2.4013e-02	0.3127
ENSG00000122912.13,SLC25A16	ACC	AZD.0530	EAG	2.0960e-02	0.3195
ENSG00000122912.13,SLC25A16	BLCA	Gefitinib	EAG	9.7811e-03	-0.1988
chr10:68478533-68482168:-	BLCA	EHT.1864	EER	2.0643e-02	0.1927
chr10:68517572-68525623:-	BRCA	GNF.2	EER	6.4454e-03	-0.1619
ENSG00000122912.13,SLC25A16	BRCA	CCT007093	EAG	2.7376e-06	0.1527
chr10:68478533-68482168:-	BRCA	CCT007093	EER	2.5107e-09	0.1952
chr10:68478533-68482168:-	CESC	Bosutinib	EER	1.0548e-03	-0.2702
chr10:68517572-68525623:-	CESC	AZD.2281	EER	1.1116e-02	-0.4897
ENSG00000122912.13,SLC25A16	CESC	Gefitinib	EAG	1.1878e-03	-0.2589
chr10:68478533-68482168:-	CHOL	ABT.888	EER	4.2383e-02	-0.4009
ENSG00000122912.13,SLC25A16	CHOL	ABT.888	EAG	3.6834e-03	-0.5305
chr10:68517572-68525623:-	COAD	GSK.650394	EER	8.6412e-05	0.6932
ENSG00000122912.13,SLC25A16	COAD	BI.2536	EAG	2.0262e-07	0.3993
chr10:68478533-68482168:-	COAD	Gefitinib	EER	1.6425e-03	-0.2583
chr10:68478533-68482168:-	ESCA	CGP.60474	EER	4.2333e-02	-0.1688
ENSG00000122912.13,SLC25A16	ESCA	CEP.701	EAG	3.6337e-03	-0.2294
chr10:68517572-68525623:-	ESCA	Bleomycin	EER	4.5722e-03	-0.2400
ENSG00000122912.13,SLC25A16	GBM	DMOG	EAG	3.5020e-03	-0.2838
chr10:68478533-68482168:-	GBM	DMOG	EER	3.8521e-03	-0.2837
chr10:68478533-68482168:-	HNSC	AZD.0530	EER	1.3575e-03	-0.2431
ENSG00000122912.13,SLC25A16	HNSC	AZD.0530	EAG	1.5516e-03	-0.2362
chr10:68478533-68482168:-	KICH	A.443654	EER	3.8829e-04	-0.4617
ENSG00000122912.13,SLC25A16	KICH	A.443654	EAG	3.3740e-04	-0.4620
ENSG00000122912.13,SLC25A16	KIRC	AZD6482	EAG	1.2273e-03	0.1688
chr10:68517572-68525623:-	KIRC	FH535	EER	2.0002e-02	-0.2409
chr10:68478533-68482168:-	KIRC	BMS.509744	EER	5.1253e-06	-0.2361
chr10:68478533-68482168:-	KIRP	Cisplatin	EER	8.6105e-03	0.1632
chr10:68517572-68525623:-	KIRP	Cyclopamine	EER	6.6092e-03	0.2875
ENSG00000122912.13,SLC25A16	KIRP	GSK269962A	EAG	1.3226e-04	0.2353
chr10:68517572-68525623:-	LAML	GDC0941	EER	1.5439e-03	0.3462
ENSG00000122912.13,SLC25A16	LAML	GDC0941	EAG	1.4000e-02	0.2656
ENSG00000122912.13,SLC25A16	LGG	ATRA	EAG	1.7043e-03	-0.1453
chr10:68478533-68482168:-	LGG	CGP.082996	EER	9.4555e-04	-0.1533
chr10:68517572-68525623:-	LIHC	MG.132	EER	4.3622e-03	-0.3368
ENSG00000122912.13,SLC25A16	LIHC	AZ628	EAG	7.7465e-03	0.1550
chr10:68478533-68482168:-	LIHC	AZ628	EER	1.5215e-02	0.1434
chr10:68517572-68525623:-	LUAD	ABT.888	EER	1.3682e-03	-0.2422
ENSG00000122912.13,SLC25A16	LUAD	JNK.Inhibitor.VIII	EAG	5.4270e-05	-0.1963
chr10:68478533-68482168:-	LUAD	Docetaxel	EER	8.8111e-05	-0.1950
ENSG00000122912.13,SLC25A16	LUSC	Dasatinib	EAG	2.4029e-03	0.1814
chr10:68478533-68482168:-	LUSC	BIRB.0796	EER	4.3320e-03	-0.1879
chr10:68517572-68525623:-	LUSC	CGP.082996	EER	4.9353e-03	0.2892
ENSG00000122912.13,SLC25A16	MESO	BIRB.0796	EAG	7.0860e-03	0.4095
chr10:68478533-68482168:-	MESO	BMS.708163	EER	1.6797e-03	-0.4987
chr10:68478533-68482168:-	OV	Etoposide	EER	1.1512e-03	0.2183
ENSG00000122912.13,SLC25A16	OV	Etoposide	EAG	3.7576e-02	0.1357
ENSG00000122912.13,SLC25A16	PRAD	Erlotinib	EAG	3.7608e-05	-0.1843
chr10:68478533-68482168:-	PRAD	Erlotinib	EER	6.6735e-05	-0.1784
ENSG00000122912.13,SLC25A16	READ	CI.1040	EAG	4.5661e-02	0.3064
chr10:68478533-68482168:-	READ	CI.1040	EER	4.5977e-02	0.3060
ENSG00000122912.13,SLC25A16	SARC	BAY.61.3606	EAG	1.7885e-03	0.2800
chr10:68478533-68482168:-	SARC	BAY.61.3606	EER	1.1675e-03	0.2906
chr10:68478533-68482168:-	SKCM	Epothilone.B	EER	5.8108e-03	0.1743
chr10:68517572-68525623:-	SKCM	Bexarotene	EER	4.1950e-02	-0.2421
ENSG00000122912.13,SLC25A16	SKCM	Epothilone.B	EAG	1.1158e-03	0.1973
chr10:68504106-68505303:-	STAD	AG.014699	EER	1.8709e-02	0.3492
chr10:68478533-68482168:-	STAD	GW843682X	EER	1.4627e-03	-0.1857
ENSG00000122912.13,SLC25A16	STAD	GW843682X	EAG	5.5500e-03	-0.1579
chr10:68478533-68482168:-	TGCT	Docetaxel	EER	2.4987e-06	-0.3911
ENSG00000122912.13,SLC25A16	TGCT	Docetaxel	EAG	8.5582e-05	-0.3281
chr10:68478533-68482168:-	THCA	GSK269962A	EER	4.3803e-08	-0.2472
ENSG00000122912.13,SLC25A16	THCA	GSK269962A	EAG	4.3803e-08	-0.2472
chr10:68478533-68482168:-	THYM	AZD6244	EER	1.3112e-06	-0.5481
ENSG00000122912.13,SLC25A16	THYM	AZD6244	EAG	2.0030e-06	-0.5401
chr10:68478533-68482168:-	UCEC	CGP.60474	EER	2.0638e-04	-0.4803
ENSG00000122912.13,SLC25A16	UCEC	CGP.60474	EAG	1.6339e-04	-0.4715
ENSG00000122912.13,SLC25A16	UCS	CEP.701	EAG	2.9475e-02	-0.4273
ENSG00000122912.13,SLC25A16	UVM	EHT.1864	EAG	1.1247e-02	-0.3592
chr10:68478533-68482168:-	UVM	EHT.1864	EER	1.0612e-02	-0.3619

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType